Premium
Peroxisome proliferator‐activated receptors in tumorigenesis: Targets of tumour promotion and treatment
Author(s) -
RobertsThomson Sarah J
Publication year - 2000
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1046/j.1440-1711.2000.00921.x
Subject(s) - fibrate , peroxisome proliferator activated receptor , thiazolidinedione , receptor , transcription factor , peroxisome proliferator activated receptor gamma , peroxisome proliferator activated receptor alpha , carcinogenesis , peroxisome , biology , nuclear receptor , microbiology and biotechnology , cancer research , endocrinology , biochemistry , diabetes mellitus , gene , type 2 diabetes , cholesterol
The peroxisome proliferator‐activated receptors (PPAR) are ligand‐activated transcription factors. There are three genes that code for the PPAR isoforms: PPARα, PPARβ and PPARγ. In the present review, studies characterizing the various PPAR isoforms are discussed. Peroxisome proliferator‐activated receptor α has been implicated in the lipid‐lowering effects of the fibrate drugs. Peroxisome proliferator‐activated receptor γ has a clear role in adipocyte differentiation and is therapeutically targeted by the thiazolidinedione drugs for the treatment of type II diabetes. The physiological role of PPARβ is less well understood but, as described in the present review, recent studies have implicated it with a role in colon cancer. In the present review, particular attention is focused on the role of PPAR in the regulation of expression of proteins associated with cell cycle control and tumorigenesis.